Compare Garmin Ltd. (GRMN) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Garmin Ltd. vs GSK plc — how do they compare? Garmin Ltd. trades at $268.14 (market cap $51.77B), while GSK plc trades at $46.64 (market cap $91.88B). The key difference: GSK plc is the larger of the two by market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold Garmin Ltd. for 83 Days and GSK plc for 93 Days on average.
| GRMN | GSK | |
|---|---|---|
Market Cap | $51.77B | $91.88B |
Volume | 961,398 | 7,730,529 |
Sector | Technology | Health |
52-Week High | $313.16 | $61.18 |
52-Week Low | $187.10 | $43.24 |
Typical Hold Time | 83 Days | 93 Days |
Enterprise Value | $49.28B | $111.88B |
Dividend Yield | 1.56% | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Garmin (GRMN) trades at $268.51, down 2.77% today, amid a bearish technical signal. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue and net income show steady growth, reaching $7.25B and $1.66B in 2025, respectively, supported by strong profitability margins. Recent news highlights product innovations and industry awards, reinforcing its market position.
The outlook remains positive given earnings momentum and a consensus price target of $320.25, implying significant upside. However, high valuation ratios and bearish technical indicators pose near-term risks. Investors should weigh strong fundamentals against potential volatility and competitive pressures in the consumer electronics space.
GSK trades at $46.45, down 1.21% with bearish technical signals. The company shows strong fundamentals with revenue growth to $32.67B in 2025 and consistent earnings beats. Valuation metrics appear reasonable with P/E of 14.89 and EV/EBITDA of 8.75. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite near-term technical weakness.
GSK presents a mixed outlook with strong profitability and pipeline expansion offset by technical bearishness and HIV patent concerns. The company's 29.73% ROE and recent earnings outperformance support investment appeal, while the bearish moving average signal and competitive pressures warrant caution. Analyst consensus leans hold with 55% neutral rating, suggesting balanced risk-reward for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Garmin Ltd.
Garmin produces GPS-enabled hardware and software for five verticals: fitness, outdoors, auto, aviation, and marine. The company relies on licensing mapping data to enable its hardware specialized for often niche activities like scuba diving or sailing. Garmin operates in 100 countries and sells its products via distributors as well as relationships with original equipment manufacturers.
Read more on GRMN →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
